NIH launched trial to study allergic reactions to COVID-19 mRNA vaccine
On Mar. 9, 2022, researchers from the National Institute of Allergy and Infectious Diseases (NIAID) announced a clinical…
Innovation Pharmaceuticals reported additional findings from Brilacidin phase 2 COVID-19 tial results
On Mar. 7, 2022, Innovation Pharma announced the Company was conducting full data analysis of the Phase 2…
Novavax announced extended durability of protection against infection and disease in UK COVID-19 vaccine phase 3 clinical Trial
On Feb. 24, 2022, Novavax shared extended analysis from its pivotal Phase 3 clinical trial conducted in the…
The University of Virginia Cancer Center Received NCI Comprehensive Designation
On Feb. 1, 2022, University of Virginia Cancer Center announced it had been awarded a Comprehensive Cancer Center…
Novavax files for conditional Marketing Authorization of COVID-19 vaccine in Switzerland
On Feb. 14, 2022, Novavax announced its submission to Swissmedic, the Swiss Agency for Therapeutic Products, for conditional…
First-in-human implant of ‘closed-loop’ bioelectronic research system begun for Parkinson’s-like Multiple Systems Atrophy
On Feb. 8, 2022, researchers at Oxford University announced they had implanted a novel closed-loop research platform for…
Study of Penn patients with decade-long leukemia remissions after CAR T cell therapy revealed new details about persistence of personalized ‘Living Drug’ cells
On Feb. 2, 2022, a new analysis of the first two patients treated in a clinical trial with…
Novavax submitted request to U.S. FDA for Emergency Use Authorization of COVID-19 vaccine
On Jan. 31, 2022, Novavax announced that it had submitted a request to the U.S Food and Drug…
Hyperimmune intravenous immunoglobulin does not improve outcomes for adults hospitalized with COVID-19
On Jan. 27, 2022, NIAID announced that a clinical trial found that the combination of remdesivir plus a…
COVID-19 | FDA | Life Science History | NIH
Mix-and-match trial found additional dose of COVID-19 vaccine safe, immunogenic
On Jan. 26, 2022, the NIH announced that adults who had previously received a full regimen of any…
Oral immunotherapy induced remission of peanut allergy in some young children
On Jan. 20, 2022, a clinical trial funded by the National Institutes of Health found that giving peanut…
Novartis and Molecular Partners reported positive topline data from Phase 2 study for ensovibep antiviral therapeutic for COVID-19
On Jan. 10, 2022, Novartis Molecular Partners announced that Part A of the EMPATHY clinical trial that compared…
Revelar Biotherapeutics and Twist Bioscience announced RBT-0813 neutralized SARS-CoV-2 Omicron and Delta variants
On Jan 5, 2022, Revelar Biotherapeutics and Twist Bioscience announced that RBT-0813 binded to and neutralized the Omicron…
Pfizer and BioNTech submit updated longer-term follow-up data of COMIRNATY in adolescents to EMA
On Dec. 23, 2021, Pfizer and BioNTech announced that they had submitted longer-term follow-up data from the companiesﾒ…
Novavax announced initiation of PREVENT-19 COVID-19 vaccine phase 3 trial booster study
On Dec. 21, 2021, Novavax announced that the first booster doses of NVX-CoV2373, the company’s recombinant nanoparticle protein-based…
Novavax filed for Emergency Use of COVID-19 vaccine in the United Arab Emirates
On Dec. 13, 2021, Novavax announced that it had submitted a regulatory filing to the Ministry of Health…
Novavax filed for interim authorization of COVID-19 vaccine in singapore
On Nov. 24, 2021, Novavax announced its submission to the Singapore Health Sciences Authority for interim authorization of…
Innovation Pharmaceuticals conducted full data analysis of phase 2 brilacidin COVID-19 trial results to support inclusion in Government-sponsored trials
On Nov. 12, 2021, Innovation Pharma announced the Company was conducting full data analysis of the Phase 2…
Innovation Pharmaceuticals announced topline results from phase 2 clinical trial of brilacidin for COVID-19
On Nov. 11, 2021, Innovation Pharma reported topline results from the Companyﾒs Phase 2 clinical trial of Brilacidin…
Database lock completed for Innovation Pharmaceuticalsﾒ phase 2 clinical trial of brilacidin for COVID-19
On Nov. 3, 2021, Innovation Pharma announced that the Company had received confirmation that hard lock of the…
Relief Therapeutics reported positive interim data from trial of novel nasal spray Sentinox in SARS-CoV-2 infected patients
On Oct. 27, 2021, RELIEF THERAPEUTICS announced that its wholly owned subsidiary, APR Applied Pharma Research, reported positive…
Vaxart dosed first subject in phase II COVID-19 oral tablet vaccine clinical trial
On Oct. 26, 2021, Vaxart announced that it has dosed the first subject in its Phase II COVID-19…
Axcella Therapeutics launched clinical program to develop treatment for patients with long COVID
On Oct. 26, 2021, Axcella Therapeutics announced a new clinical program to investigate AXA1125 as a potential treatment…
Subcutaneous Interferon does not improve outcomes for hospitalized adults with COVID-19
On Oct. 18, 2021, a NIAID sponsored clinical trial found that treatment with the immunomodulator interferon beta-1a plus…
LogicBio Therapeutics announced early clinical trial results demonstrated first-ever in vivo genome editing in children
On Oct. 18, 2021, LogicBio Therapeutics announced clinical trial results that demonstrated the first-ever in vivo genome editing…
Vaxartﾠbegan recruiting in global phase II COVID-19 oral tablet vaccine clinical trial
On Oct. 6, 2021, Vaxart announced that it had begun recruiting subjects for its Phase II COVID-19 oral…
Washington University School of Medicine in St. Louis led pediatric COVID-19 vaccine trial launched
On Oct. 6, 2021, Washington University School of Medicine announced the start of a pediatric COVID-19 vaccine clinical…
Pfizer announced Study of mRNA-based next generation flu vaccine program
On Sept. 27, 2021, Pfizer announced that the first participants have been dosed in a Phase 1 clinical…
Results from Novavax NanoFlu influenza vaccine phase 3 clinical trial Published in The Lancet Infectious Diseases
On Sept. 23, 2021, Novavax announced publication of complete results from a pivotal Phase 3 clinical trial of…
Clover Biopharmaceuticals’s vaccine using Dynavax’s CpG 1018 adjuvant met primary and secondary efficacy endpoints
On Sept. 22, 2021, Dynavax Technologies announced that Clover Biopharmaceuticals reported positive data for their protein-based COVID-19 vaccine…